Get started
Author

V.O. Leonova

The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC
2024 · Jhanelle E. Gray, Michael Schenker, et al. · Journal of Thoracic Oncology · 12
PDF
Management of Patients With St-segment Elevation Acute Coronary Syndrome in Interventional Cardiology Units: Record-3 Registry Data
2016 · O.L. Barbarash, V.V. Kashtalap, et al. · Fundamental and Clinical Medicine · 5
PDF
Assessment of Risk of Bleeding in Myocardial Infarction With St Segment Elevation
2018 · A.M. Kochergina, V.O. Leonova, et al. · Siberian medical review · 2
PDF
MA11.07 Pembrolizumab Plus Maintenance Olaparib as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study
2024 · J. Gray, M. Schenker, et al. · Journal of Thoracic Oncology · 1
PDF
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy
2024 · Hochmair M, Schenker M, et al. · Newcastle University ePrints (Newcastle Univesity)
PDF
Preparation of Patients for Elective Percutaneous Coronary Intervention: Management of Risk Factors as an Approach to Increase in Intervention Efficacy
2019 · A. Kochergina, V. Leonova, et al. · Medical University
Clinical predictors of hemorrhagic complications in ST segment elevation acute myocardial infarction
2016 · A.M. Kochergina, V.V. Kashtalap, et al. · Russian Heart Journal
Works count: 7
Citation count: 20
H-index: 2
I10-index: 1
Year
Topic
Type